reports
Autolus Therapeutics to Report Third Quarter 2025 Financial Results an...
Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025 LONDON & GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its third quarter 2025 financial results and operational highlights before open of U.S. markets on Wednesday, November 12, 2025. Management will host a conference call and webcast at 8:30am EST / 1:30pm...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
BioNTech veranstaltet am 11. November 2025 „Innovation Series Day“ zu ...
BioNTech veranstaltet am 11. November 2025 „Innovation Series Day“ zu Forschung & Entwicklung MAINZ, Deutschland, 28. Oktober 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) veranstaltet am Donnerstag, 11. November 2025 um 15:00 Uhr MEZ (09:00 Uhr EST) in New York City, USA, eine Ausgabe der „Innovation Series“ des Unternehmens mit Schwerpunkt auf Forschung & Entwicklung. Bei der Veranstaltung werden Mitglieder der Führungsebene des Unternehmens ein Update zu BioNTechs Strategie sowie einen Überblick über die Fortschritte in der Pipeline geben. Die Veranstaltu...
BioNTech to Host Innovation Series R&D Day on November 11, 2025
BioNTech to Host Innovation Series R&D Day on November 11, 2025 MAINZ, Germany, October 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of the Company’s Innovation Series R&D Day at 09:00 a.m. Eastern Standard Time (3:00 p.m. CET) on Tuesday, November 11, 2025 in New York City, U.S. On the day, members of BioNTech’s leadership team will provide an overview of the Company’s strategy and clinical progress across its pipeline. Investors, analysts and the interested public are invited to join the event online via this . A replay of the webcas...
- Jacob Mekhael
Autolus Aucatzyl phase 1 maintains SLE responses with longer follow up
Autolus announced that follow-up data from the ongoing phase 1 (CARLYSLE) dose confirmation trial of Aucatzyl (obe-cel, CD19 CAR-T) in severe refractory systemic lupus erythematosus (srSLE), will be presented during a poster session at the American College of Rheumatology Convergence 2025. The updated results demonstrate durability of outcomes observed in the initial readout (presented April 2025) over a longer follow up period as evidenced by the absence of new disease activity, no other lupus ...
- Jacob Mekhael
- Michiel Declercq
- Thomas Couvreur
BioNTech veröffentlicht am 3. November 2025 Ergebnisse für das dritte ...
BioNTech veröffentlicht am 3. November 2025 Ergebnisse für das dritte Quartal 2025 und informiert über operativen Fortschritt MAINZ, Deutschland, 27. Oktober 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird am Montag, den 3. November 2025, die Ergebnisse für das dritte Quartal 2025 veröffentlichen. Darüber hinaus wird das Unternehmen am selben Tag um 14:00 Uhr MEZ (8:00 Uhr Eastern Standard Time) eine Telefonkonferenz samt Webcast für Investoren, Finanzanalysten sowie die allgemeine Öffentlichkeit durchführen, um die Finanzergebnisse sowie ein Unternehmensupd...
BioNTech to Report Third Quarter 2025 Financial Results and Corporate ...
BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025 MAINZ, Germany, October 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2025 on Monday, November 3, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EST (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this . On...
Autolus Therapeutics Presents Clinical Data Updates at the American Co...
Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025 Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS or high-grade CRS; 50 million cell dose selected for Phase 2 pivotal studyPreliminary efficacy data demonstrate achievement of definition of remission in SLE (DORIS) in 83% of patients and complete renal response (CRR) in 50% of patients; all responses and remissions are ongoing with no evidence of disease activity at a median follow-up of 8....
BioNTech beginnt öffentliches Umtauschangebot für alle ausstehenden Ak...
BioNTech beginnt öffentliches Umtauschangebot für alle ausstehenden Aktien von CureVac N.V. Geplante Übernahme soll Forschung, Entwicklung, Herstellung und Kommerzialisierung von mRNA-basierten Krebsimmuntherapie-Kandidaten stärken und ist ein weiterer Meilenstein in der Umsetzung von BioNTechs Onkologie-StrategieCureVac-Aktionärinnen und -Aktionäre erhalten für jede CureVac-Aktie BioNTech American Depositary Shares im Wert von ca. 5,46 US-Dollar, wobei das Umtauschverhältnis einem Anpassungsmechanismus unterliegt; ein Richtwert für das Umtauschverhältnis wird während der Laufzeit des Umtau...
BioNTech Commences Public Exchange Offer for All Outstanding Shares of...
BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V. Acquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next milestone in the execution of its oncology strategyCureVac shareholders receive approximately $5.46 in BioNTech American Depositary Shares for each CureVac share, subject to a collar; an indicative exchange ratio will be available at for the duration of the exchange offerInformation on how CureVac shareholders can participate in the exchange off...
- Jacob Mekhael
Autolus Doses first patient in phase 1 trial of Aucatzyl in progressiv...
Yesterday, before US market opens, Autolus announced that the first patient has been dosed in the phase 1 (BOBCAT, NCT07139743) trial of Aucatzyl (obe-cel, CD19 CAR-T) in patients with progressive multiple sclerosis (PMS). This comes in line with the company's previously guided timeline to initiate the trial by YE25. While relapsing MS has multiple treatment options, there remains a need to address the progressive form of the disease, which is characterised by CNS-compartmentalised inflammation....
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Thomas Couvreur
Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of...
Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis LONDON and Gaithersburg, Md., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the first patient has been dosed in its Phase 1 BOBCAT trial of obecabtagene autoleucel (obe-cel) in patients with progressive multiple sclerosis (PMS). The patient was treated at Univ...
- Baptiste Salaville
- Bruno Cavalier
- Roy Külter
- Steven Boumans
ORA ORANGE SA
EO FAURECIA SA
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
EN BOUYGUES SA
TNG TRANSGENE SA
SCR SCOR SE
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
VIRP VIRBAC SA
KER KERING SA
TPE PVA TEPLA AG
ISP INTESA SANPAOLO S.P.A.
01913 PRADA S.P.A.
AIXA AIXTRON SE
DLG DE'LONGHI S.P.A.
UCG UNICREDIT S.P.A.
MONC MONCLER SPA
VIG VIENNA INSURANCE GROUP AG WIENER VERSICHERUNG GRUPPE
VGP VGP NV
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
COFA COFACE SA
ALM ALMIRALL SA
ZGN ERMENEGILDO ZEGNA NV
ARYN ARYZTA AG
- Baptiste Salaville
- Bruno Cavalier
- Roy Külter
- Steven Boumans
ORA ORANGE SA
EO FAURECIA SA
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
EN BOUYGUES SA
TNG TRANSGENE SA
SCR SCOR SE
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
VIRP VIRBAC SA
KER KERING SA
TPE PVA TEPLA AG
ISP INTESA SANPAOLO S.P.A.
01913 PRADA S.P.A.
AIXA AIXTRON SE
DLG DE'LONGHI S.P.A.
UCG UNICREDIT S.P.A.
MONC MONCLER SPA
VIG VIENNA INSURANCE GROUP AG WIENER VERSICHERUNG GRUPPE
VGP VGP NV
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
COFA COFACE SA
ALM ALMIRALL SA
ZGN ERMENEGILDO ZEGNA NV
ARYN ARYZTA AG
- Martial Descoutures
- Oussema Denguir
- Martial Descoutures
- Oussema Denguir
Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive ...
Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid tumors to improve response to cancer immunotherapy Strasbourg, France, and Lund, Sweden, October 20, 2025, 08:30 a.m. CEST – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment...
Le virus oncolytique armé BT-001, développé par Transgene et BioInvent...
Le virus oncolytique armé BT-001, développé par Transgene et BioInvent, montre une activité antitumorale locale, à distance et durable chez des patients atteints de tumeurs avancées en échec thérapeutique BT-001, administré en combinaison avec pembrolizumab, est bien toléré et présente une activité antitumorale persistante dans des lésions injectées et non-injectées Les résultats obtenus soutiennent la poursuite du développement de BT-001 dans les tumeurs solides afin d'améliorer la réponse aux immunothérapies Strasbourg, France, et Lund, Suède, le 20 octobre 2025, 8 h 30 CEST – Transge...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.